CALR and neoplasm: Second, studies in colon cancer cells have shown that oxaliplatin can stimulate cancer cells to expose proapoptotic calreticulin (CRT), which is required for immunogenic cell death (ICD), and advocate for the effectiveness of anti-tumor therapy (73).